Quick Answer
Tempest Therapeutics, Inc. reported Long Term Debt of $0.00 for the year ending 2024.
- Tempest Therapeutics, Inc. showed a decrease of -100.0% in Long Term Debt from 2023 to 2024.
- This data is from Tempest Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2025.
- XBRL data for this metric is available from 2017 to 2024 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $325.0 thousand | Q2 2019: $278.0 thousand | Q3 2019: $218.0 thousand | Q1 2020: $110.0 thousand | Q2 2020: $168.0 thousand | Q3 2020: $0.00 | Q4 2020: $0.00 | Q1 2021: $15.07 million | Q2 2021: $14.92 million | Q3 2021: $15.01 million | Q1 2022: $15.13 million | Q2 2022: $13.30 million | Q3 2022: $11.84 million | Q1 2023: $8.94 million | Q2 2023: $7.48 million | Q3 2023: $8.37 million | Q1 2024: $4.14 million | Q2 2024: $2.01 million | Q3 2024: $0.00.
- Over the full 8 years of available data (2017 to 2024), Tempest Therapeutics, Inc.'s Long Term Debt has declined by 100.0%.
- Historical annual values: Fiscal year 2024: $0.00 | Fiscal year 2023: $6.26 million | Fiscal year 2022: $10.37 million | Fiscal year 2021: $15.07 million | Fiscal year 2020: $61.0 thousand | Fiscal year 2019: $168.0 thousand | Fiscal year 2018: $383.0 thousand | Fiscal year 2017: $599.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: